Evidence map›Paper›PMID 32383805›Full record

ArticleHuman psychopharmacology2020

Association of ANKK1 polymorphism with antipsychotic-induced hyperprolactinemia.

Olga Yu Fedorenko, Diana Z Paderina, Anton J M Loonen, Ivan V Pozhidaev, Anastasiia S Boiko, Elena G Kornetova, Nikolay A Bokhan, Bob Wilffert, Svetlana A Ivanova

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human psychopharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Olga Yu FedorenkoMental Health Research Institute, Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russia.ORCID 0000-0002-9565-6314
Diana Z PaderinaMental Health Research Institute, Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russia.ORCID 0000-0002-5546-7316
Anton J M LoonenPharmacoTherapy, -Epidemiology and -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands.ORCID 0000-0003-4942-6195
Ivan V PozhidaevMental Health Research Institute, Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russia.ORCID 0000-0003-1238-7495
Anastasiia S BoikoMental Health Research Institute, Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russia.ORCID 0000-0002-2955-9057
Elena G KornetovaMental Health Research Institute, Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russia.ORCID 0000-0002-5179-9727
Nikolay A BokhanMental Health Research Institute, Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russia.ORCID 0000-0002-1052-855X
Bob WilffertPharmacoTherapy, -Epidemiology and -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands.ORCID 0000-0002-8759-5697
Svetlana A IvanovaMental Health Research Institute, Tomsk National Research Medical Center of Russian Academy of Sciences, Tomsk, Russia.ORCID 0000-0001-7078-323X
Russian Academy of Sciences · RUUniversity Medical Center Groningen · NLUniversity of Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveSchizophrenia is a severe highly heritable mental disorder. Genetic polymorphisms of dopaminergic pathways are related to pathogenesis of drug response. Hyperprolactinemia (HPRL), a common adverse effect of antipsychotics, is attributed to blockade of dopamine D2 receptors. Ankyrin Repeat and Kinase Domain containing 1 (ANKK1) gene is closely related to Dopamine Receptor D2 type (DRD2) gene functioning. We examined whether the functional polymorphism rs2734849 in the ANKK1 gene is associated with antipsychotic-induced HPRL.

methodsWe recruited 446 patients with schizophrenia from among the Russian population of the Siberian region. The polymorphism rs2734849 in the ANKK1 gene was genotyped with The MassARRAY® Analyzer 4 by Agena Bioscience™, using the kit SEQUENOM Consumables iPLEXGold 384. Genotype and allele frequencies were compared between groups of schizophrenia patients with and without HPRL using the χ

resultsA comparison between schizophrenia patients with and without HPRL revealed significantly higher frequency of the C allele of the polymorphic variant rs2734849 in the ANKK1 gene in patients with HPRL as compared to the patients without it (χ

conclusionThe functional polymorphism rs2734849 in the ANKK1 gene was associated with HPRL in patients with schizophrenia.

Indexed as

AdultAntipsychotic AgentsFemaleGene FrequencyGenetic Predisposition to DiseaseGenotypeHumansHyperprolactinemiaMaleMiddle AgedPolymorphism, Single NucleotideProtein Serine-Threonine KinasesReceptors, Dopamine D2SchizophreniaSiberiaANKK1 protein, humanAntipsychotic AgentsDRD2 protein, humanProtein Serine-Threonine KinasesReceptors, Dopamine D2ANKK1hyperprolactinemiapolymorphismschizophrenia

Identifiers

PMID32383805
PMCPMC7507142
OpenAlexW3023612283

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.